

CLAIMS

1. Use of a farnesyltransferase inhibitor (FTI) in the manufacture of a medicament for the treatment of an EGFR inhibitor-refractory squamous cell carcinoma of the head and neck (SCCHN) in a subject, wherein the SCCHN has an HRAS mutation.

2. The use of claim 1, wherein said HRAS mutation comprises an amino acid substitution at a codon selected from a group consisting of G12, G13, Q61, Q22, K117, A146, and any combination thereof.

3. The use of claim 1 or 2, wherein said SCCHN does not have K-Ras mutation or N-Ras mutation.

4. The use of claim 3, wherein said SCCHN has wild type K-Ras and wild type N-Ras.

5. The use of claim 1 to 4, wherein said SCCHN is HPV negative.

6. The use of claim 1 to 5, wherein said SCCHN is recurrent or metastatic.

7. The use of claim 1 to 6, wherein said SCCHN is relapsed SCCHN.

8. The use of claim 1 to 7, wherein the SCCHN is SCCHN of the trachea.

9. The use of claim 1 to 7, wherein the SCCHN is SCCHN of the maxilla.

10. The use of claim 1 to 7, wherein the SCCHN is SCCHN of the oral cavity.

11. The use of claim 1 to 10, wherein the EGFR inhibitor is cetuximab.

12. The use of claim 1 to 11, wherein the FTI is tipifarnib.

13. Use of a farnesyltransferase inhibitor (FTI) in the manufacture of a medicament for the treatment of EGFR inhibitor-refractory lung squamous cell carcinoma (lung SCC) in a subject, wherein the lung SCC has an HRAS mutation.

14. The use of claim 13 or 14, wherein said HRAS mutation comprises an amino acid substitution at a codon selected from a group consisting of G12, G13, Q61, Q22, K117, A146, and any combination thereof.

15. The use of claim 13, wherein said lung SCC does not have K-Ras mutation or N-Ras mutation.

16. The use of claim 15, wherein said lung SCC has wild type K-Ras and wild type N-Ras.

17. The use of any one of claims 13 to 16, wherein said lung SCC is HPV negative.
18. The use of any one of claims 13 to 17, wherein said lung SCC is at an advanced stage or metastatic.
19. The use of any one of claims 13 to 18, wherein said lung SCC is relapsed lung SCC.
20. The use of any one of claims 13 to 19, wherein the EGFR inhibitor is cetuximab.
21. The use of any one of claims 13 to 20, wherein the FTI is tipifarnib.